Understand the source comparison
Top Selling Peptides March 2026: Category Comparison
Here's how the leading peptide categories compare across mechanism, research applications, and stability requirements. Tirzepatide Dual GIP/GLP-1 receptor agonist Metabolic disease, insulin sensitivity, NAFLD 2–8°C (reconstituted) ~5 days Most versatile metabo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's how the leading peptide categories compare across mechanism, research applications, and stability requirements.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- Metabolic disease, insulin sensitivity, NAFLD
- 2–8°C (reconstituted)
- ~5 days
- Most versatile metabolic peptide for comparative dual-agonist studies
- BPC-157
- Angiogenesis, VEGF upregulation, collagen synthesis
- Soft tissue repair, GI healing, tendon/ligament injury
- Room temp (powder), 2–8°C (reconstituted)
- 4 hours (systemic)
- Widest tissue repair application range; stable and cost-effective
- Dihexa
- HGF receptor agonist, synaptogenesis
- Neurodegenerative disease, cognitive decline, TBI models
- ~3 hours
- Most potent neuroplasticity compound; oral bioavailability simplifies protocols
- Thymosin Alpha-1
- T-cell maturation, interferon-gamma production
- Immune senescence, vaccine response, chronic infection
- ~2 hours
- Leading immune modulation peptide for aging and oncology research
- Retatrutide
- Triple GIP/GLP-1/GCG receptor agonist
- Metabolic disease, energy expenditure, hepatic glucose output
- ~6 days
- Next-generation metabolic tool; glucagon pathway adds unique research angle
- Semaglutide
- GLP-1 receptor agonist
- Metabolic disease, appetite regulation, cardiovascular outcomes
- Reference standard for single-pathway GLP-1 research; most clinical validation